AlgentBio

Algent Bio is a clinical-stage biotechnology company focused on developing innovative chimeric antigen receptor (CAR) T-cell therapies for solid tumors and hematological malignancies. The company utilizes proprietary technology to overcome the challenges of the immunosuppressive tumor microenvironment, specifically targeting antigens like GPC3 and Claudin 18.2. With a pipeline of next-generation cell therapies, Algent Bio aims to improve clinical outcomes for patients with advanced cancers such as liver and gastric carcinoma. The firm operates primarily out of China's biotech hubs, maintaining a strong focus on translational research and clinical development. Their lead programs are currently in early-phase clinical trials, demonstrating the company's commitment to moving from bench to bedside.